Show simple item record

dc.contributor.authorChittasupho, Chuda
dc.contributor.authorManikwar, Prakash
dc.contributor.authorKrise, Jeffrey P.
dc.contributor.authorSiahaan, Teruna J.
dc.contributor.authorBerkland, Cory J.
dc.identifier.citationChittasupho, C., Manikwar, P., Krise, J. P., Siahaan, T. J., & Berkland, C. (2010). cIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cells. Molecular Pharmaceutics, 7(1), 146.
dc.description.abstractLeukocyte function associated antigen-1 (LFA-1) is a primary cell adhesion molecule of leukocytes required for mediating cellular transmigration into sites of inflammation via the vascular endothelium. A cyclic peptide, cIBR, possesses high affinity for LFA-1 and conjugation to the surface of poly(dl-lactic-co-glycolic acid) nanoparticles can specifically target and deliver the encapsulated agents to T cells expressing LFA-1. The kinetics of targeted nanoparticle uptake by acute lymphoblastic leukemia T cells was investigated by flow cytometry and microscopy and compared to untargeted nanoparticles. The specificity of targeted nanoparticles binding to the LFA-1 integrin was demonstrated by competitive inhibition using free cIBR peptide or using the I domain of LFA-1 to inhibit the binding of targeted nanoparticles. The uptake of targeted nanoparticles was concentration and energy dependent. The cIBR-conjugated nanoparticles did not appear to localize with lysosomes whereas untargeted nanoparticles were detected in lysosomes in 6 hrs and steadily accumulated in lysosomes for 24 hrs. Finally, T-cell adhesion to epithelial cells was inhibited by cIBR-nanoparticles. Thus, nanoparticles displaying the cIBR ligand may offer a useful targeted drug delivery system as an alternative treatment of inflammatory diseases involving transmigration of leukocytes.en_US
dc.publisherAmerican Chemical Societyen_US
dc.rightsThis document is the Accepted Manuscript version of a Published Work that appeared in final form in Molecular Pharmaceutics, copyright © American Chemical Society after peer review and technical editing by the publisher. To access the final edited and published work see
dc.titlecIBR effectively targets nanoparticles to LFA-1 on acute lymphoblastic T cellsen_US
kusw.kuauthorChittasupho, Chuda
kusw.kuauthorManikwar, Prakash
kusw.kuauthorKrise, Jeffrey P.
kusw.kuauthorSiahaan, Teruna J.
kusw.kuauthorBerkland, Cory J.
kusw.kudepartmentPharmaceutical Chemistryen_US
kusw.oanotesPer SHERPA/RoMEO 5/8/2017: Author's Pre-print: grey tick subject to Restrictions below, author can archive pre-print (ie pre-refereeing) Restrictions:

Must obtain written permission from Editor Must not violate ACS ethical Guidelines

Author's Post-print: grey tick subject to Restrictions below, author can archive post-print (ie final draft post-refereeing) Restrictions:

If mandated by funding agency or employer/ institution If mandated to deposit before 12 months, must obtain waiver from Institution/Funding agency or use AuthorChoice 12 months embargo

Publisher's Version/PDF: cross author cannot archive publisher's version/PDF General Conditions:

On author's personal website, pre-print servers, institutional website, institutional repositories or subject repositories Non-Commercial Must be accompanied by set statement (see policy) Must link to publisher version Publisher's version/PDF cannot be used
kusw.oaversionScholarly/refereed, author accepted manuscripten_US
kusw.oapolicyThis item meets KU Open Access policy criteria.en_US

Files in this item


This item appears in the following Collection(s)

Show simple item record